TY - JOUR
T1 - Adenosine receptors as emerging therapeutic targets for diabetic kidney disease
AU - Pak, Eun Seon
AU - Cha, Jin Joo
AU - Cha, Dae Ryong
AU - Kanasaki, Keizo
AU - Ha, Hunjoo
N1 - Funding Information:
The preparation of this manuscript was supported by a National Research Foundation grant (No. 2020R1A6A3 A13076183), Republic of Korea, and by Ewha Womans University (No. 1-2021-1301-001-1).
Publisher Copyright:
© 2022 by The Korean Society of Nephrology.
PY - 2022
Y1 - 2022
N2 - Diabetic kidney disease (DKD) is now a pandemic worldwide, and novel therapeutic options are urgently required. Adenosine, an ade-nosine triphosphate metabolite, plays a role in kidney homeostasis through interacting with four types of adenosine receptors (ARs): A1AR, A2AAR, A2BAR, and A3AR. Increasing evidence highlights the role of adenosine and ARs in the development and progression of DKD: 1) increased adenosine in the plasma and urine of diabetics with kidney injury, 2) increased expression of each of the ARs in diabetic kidneys, 3) the protective effect of coffee, a commonly ingested nonselective AR antagonist, on DKD, and 4) the protective effect of AR modulators in experimental DKD models. We propose AR modulators as a new therapeutic option to treat DKD. Detailed mechanistic studies on the pharmacology of AR modulators will help us to develop effective first-in-class AR modulators against DKD.
AB - Diabetic kidney disease (DKD) is now a pandemic worldwide, and novel therapeutic options are urgently required. Adenosine, an ade-nosine triphosphate metabolite, plays a role in kidney homeostasis through interacting with four types of adenosine receptors (ARs): A1AR, A2AAR, A2BAR, and A3AR. Increasing evidence highlights the role of adenosine and ARs in the development and progression of DKD: 1) increased adenosine in the plasma and urine of diabetics with kidney injury, 2) increased expression of each of the ARs in diabetic kidneys, 3) the protective effect of coffee, a commonly ingested nonselective AR antagonist, on DKD, and 4) the protective effect of AR modulators in experimental DKD models. We propose AR modulators as a new therapeutic option to treat DKD. Detailed mechanistic studies on the pharmacology of AR modulators will help us to develop effective first-in-class AR modulators against DKD.
KW - Adenosine
KW - Diabetic kidney disease
KW - Fibrosis
KW - Purinergic P1 receptor agonists
KW - Purinergic P1 receptor antagonists
KW - Purinergic P1 receptors
UR - http://www.scopus.com/inward/record.url?scp=85139496869&partnerID=8YFLogxK
U2 - 10.23876/j.krcp.22.011
DO - 10.23876/j.krcp.22.011
M3 - Review article
AN - SCOPUS:85139496869
SN - 2211-9132
VL - 41
SP - S74-S88
JO - Kidney Research and Clinical Practice
JF - Kidney Research and Clinical Practice
ER -